Antares Pharma Announces Next Generation of Auto-Injector Design

Emirates PharmaAdvertisement

Antares Pharma, Inc., a leader in self-injection drug delivery technology, announced the latest advancement in its proprietary line of VIBEX(TM) auto-injectors. Antares’ new VIBEX QS auto-injector platform offers a dose capacity of 1 mL and greater in a compact design. VIBEX QS achieves this advance by incorporating a novel triggering mechanism and space-saving spring configuration. The new design also accommodates fast injection of highly-viscous drug products that stall less-powerful conventional auto-injectors.

VIBEX QS is designed to enhance the patient experience with self-administered parenteral drugs including most biological agents. Of the $50 billion U.S. market for biological drugs in 2009, we estimate that self-administered products accounted for over half the total. Biological drugs in particular face new competitive threats as biosimilar drugs are approved in Europe and the U.S. Our patented VIBEX delivery systems address self-injectable product manufacturers’ growing needs for product differentiation strategies especially as differences between the active ingredients of competing products become less apparent. Many self-injectable drugs currently marketed and in clinical development are formulated to be administered in a 1 mL dose volume, which the new VIBEX QS accommodates.

Emirates PharmaAdvertisement